The pretreatment of anti-IL-6R antibody inhibited those reactions in a dose-dependent manner, indicating that IL-6R is highly expressed in certain types of ovarian cancer cells and that IL-6/IL-6R signaling exerts in a paracrine manner in these cells, even though the cells do not produce IL-6. This evidence concerns the gene IL6R and ovarian carcinoma.